Molecular detection of low-level disease in patients with cancer

Burchill, Susan A.; Selby, Peter J.

doi:10.1002/(sici)1096-9896(200001)190:1<6::aid-path486>3.0.co;2-m

Cited by 43 publications

(20 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several of these approaches rely on the ex vivo detection of mutant forms of the oncogenes and tumor suppressor genes that are responsible for the initiation and progression of tumors. This approach was first used to detect bladder and colon tumors through examination of urine and stool, respectively (9,10), and has since been used to detect several other tumor types (11)(12)(13)(14). Because the mutant genes are not only ''markers'' for cancer but also the proximate causes of tumor growth (1), they have major conceptual advantages over conventional markers such as fecal occult blood or serum PSA.…”

mentioning

confidence: 99%

“…Additionally, blood can be easily obtained from patients during routine outpatient visits, and methods for preparing and storing plasma and serum are well known and reliable. Accordingly, numerous studies have attempted to identify abnormal forms or quantities of DNA in plasma or serum (6,(11)(12)(13)(14)(15). Unfortunately, the results of many of these studies are contradictory.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Detection and quantification of mutations in the plasma of patients with colorectal tumors

Diehl

Dressman

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

1,075

827

View full text Add to dashboard Cite

The early detection of cancers through analysis of circulating DNA could have a substantial impact on morbidity and mortality. To achieve this goal, it is essential to determine the number of mutant molecules present in the circulation of cancer patients and to develop methods that are sufficiently sensitive to detect these mutations. Using a modified version of a recently developed assay for this purpose, we found that patients with advanced colorectal cancers consistently contained mutant adenomatous polyposis coli (APC) DNA molecules in their plasma. The median number of APC DNA fragments in such patients was 47,800 per ml of plasma, of which 8% were mutant. Mutant APC molecules were also detected in >60% of patients with early, presumably curable colorectal cancers, at levels ranging from 0.01% to 1.7% of the total APC molecules. These results have implications for the mechanisms through which tumor DNA is released into the circulation and for diagnostic tests based on this phenomenon.colorectal cancer ͉ plasma DNA ͉ tumor suppressor gene ͉ circulating DNA ͉ diagnosis

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

Detection and quantification of mutations in the plasma of patients with colorectal tumors

Diehl

Dressman

et al. 2005

Proc. Natl. Acad. Sci. U.S.A.

1,075

827

View full text Add to dashboard Cite

show abstract

“…This is not surprising as the amount of CK-20 mRNA in 10 pg of purified RNA will be greater than in 10 pg of nucleic acid (DNA/RNA). Previous studies have shown the method of processing samples affects the sensitivity of target gene detection by RT -PCR (Burchill and Selby, 2000), it would appear this may also be the case with NASBA. Interestingly the sensitive detection of viral RNA by NASBA is usually carried out on total nucleic acids (van Gemen et al, 1995;Damen et al, 1999;Fiscus et al, 2000).…”

Section: Discussionmentioning

confidence: 94%

“…There is now good evidence that using this method it is possible to detect disease of clinical significance (Burchill and Selby, 2000;Burchill et al, 2001). Therefore RT -PCR may increase the power of minimal residual disease and micro-metastatic disease detection in some patients with cancer, which may result in a more accurate prognosis and/or improved treatment timing or selection.…”

mentioning

confidence: 99%

“…Previous studies have shown sample processing and the method of RNA extraction to significantly contribute to the sensitivity of RT -PCR (Keilholz et al, 1998;Burchill et al, 1999) although the question of false positive or negative results has remained a challenge. It is clear even patients with haematogenously disseminated disease do not invariably have tumour cells in all bone marrow or peripheral blood samples (Burchill and Selby, 2000). This has often been interpreted as a 'false negative' result, although it most likely reflects features of the metastatic disease process such as intermittent tumour-cell shedding.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the RNA-amplification based methods RT–PCR and NASBA for the detection of circulating tumour cells

Burchill

Perebolte²,

Johnston

et al. 2002

Br J Cancer

View full text Add to dashboard Cite

Increasingly, reverse transcriptase polymerase chain reaction (RT–PCR) is used to detect clinically significant tumour cells in blood or bone marrow. This may result in a redefinition of disease-free and clinical relapse. However, its clinical utility may be limited by lack of automation or reproducibility. Recent studies have suggested nucleic acid sequence-based amplification of target RNA may be more robust. In this study, nucleic acid sequence-based amplification was established to detect melanoma, colorectal and prostate cancer cells. Nucleic acid sequence-based amplification and RT–PCR both successfully amplified target RNA in peripheral blood samples from patients with melanoma and colorectal cancer, but only RT–PCR detected PSA in blood samples from patients with prostate cancer. There was relatively good agreement between sample replicates analyzed by RT–PCR (Kappa values of one for tyrosinase, 0.67 for CK-20 and one for PSA), but less agreement when analyzed by nucleic acid sequence-based amplification. This may limit the routine use of NASBA for the detection of clinically significant disease. In summary, RT–PCR appears at present to be the most reliable and reproducible method for the detection of low-level disease in cancer patients, although prospective studies are warranted to assess the clinical utility of different molecular diagnostic methods. British Journal of Cancer (2002) 86 , 102–109. DOI: 10.1038/sj/bjc/6600014 www.bjcancer.com © 2002 The Cancer Research Campaign

show abstract

Predictive Markers and Driver Genes From Treatment Trials: Potential Utility For Early Diagnosis

Sorg¹,

Memon²,

Kim³

et al. 2017

Biomarkers in Cancer Screening and Early Detection

View full text Add to dashboard Cite

Molecular detection of low-level disease in patients with cancer

Cited by 43 publications

References 87 publications

Detection and quantification of mutations in the plasma of patients with colorectal tumors

Detection and quantification of mutations in the plasma of patients with colorectal tumors

Comparison of the RNA-amplification based methods RT–PCR and NASBA for the detection of circulating tumour cells

Predictive Markers and Driver Genes From Treatment Trials: Potential Utility For Early Diagnosis

Contact Info

Product

Resources

About